Drug intelligence / Profile preview

TX-33

Development stage: Preclinical
Lead developer: Temple ORTHOBiologics
Modality: Drug Delivery Systems
Administration: Intraarticular

Overview

**TX-33** is a preclinical intra-articular combination product being developed by Temple ORTHOBiologics for prevention of **knee arthrofibrosis** after knee trauma or surgery. It combines advanced biomaterials with an undisclosed pharmaceutical derivative, with the biomaterial component intended to support local delivery and prevention of pathological scar-tissue formation within the joint. The molecular target and specific pharmacologic mechanism have not been publicly disclosed.

Targets

TLR4 (Toll-like receptor 4)TLR2 (Toll-like Receptor 2)

Beyond the preview

Go deeper on TX-33.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TX-33.

Explore the full profile